Jubilant Life Sciences   1Q Revenues: $227 million (+31%)   1Q EBITDA: $51 million (+46%)   Comments: Revenues from the Pharmaceutical segment were up 42% to $117 million, while Life Science Ingredients were up 18% to $110 million. CMO revenues were flat, as were revenues for Drug Discovery & Development Solutions and Healthcare. Growth in the Pharmaceutical segment was driven by generics and specialty pharma. North America revenues were $92 million (+43%), India revenues were $61 million (+...